Treatment of ESBL-Producing Bacterial Infections

First-Line Treatment Options

• The American College of Physicians recommends carbapenems as the first-line treatment for serious infections caused by ESBL-producing bacteria, particularly in critically ill patients, while carbapenem-sparing alternatives should be considered for less severe infections to reduce selection pressure for carbapenem resistance 1
• Group 2 carbapenems (imipenem/cilastatin, meropenem, doripenem) are preferred for critically ill patients with high bacterial loads or when treating serious infections, as recommended by the World Journal of Emergency Surgery 2, 1
• These carbapenems have activity against non-fermentative gram-negative bacilli and are more appropriate for severe infections, according to the World Journal of Emergency Surgery 2

Moderate to Severe Infections

• Ceftazidime/avibactam plus metronidazole has demonstrated activity against ESBL-producers and some KPC-producing organisms, as reported by the International Journal of Antimicrobial Agents 1, 3
• Group 1 carbapenems like ertapenem have activity against ESBL-producing pathogens but are not active against Pseudomonas aeruginosa, according to the World Journal of Emergency Surgery 2

Special Considerations

• Ceftazidime/avibactam plus aztreonam is strongly recommended for infections caused by metallo-β-lactamase (MBL)-producing Enterobacterales, as recommended by the International Journal of Antimicrobial Agents 3
• Cefiderocol may also be considered as an alternative option for MBL-producing organisms, according to the International Journal of Antimicrobial Agents 3

Important Considerations

• Local epidemiology and resistance patterns should guide empiric therapy choices, as recommended by the Praxis Medical Insights 1, 4
• Rapid identification of the specific resistance mechanism is crucial for optimizing therapy, according to the Praxis Medical Insights 4
• In areas with high carbapenem-resistant Klebsiella pneumoniae, carbapenem-sparing regimens are strongly recommended, as reported by the Praxis Medical Insights 1, 4

Common Pitfalls to Avoid

• Overuse of carbapenems leads to selection pressure and emergence of carbapenem-resistant organisms, as warned by the Praxis Medical Insights 1
• First-generation cephalosporins lack activity against ESBL-producing organisms and should not be used, according to the Praxis Medical Insights 4
• Fluoroquinolones should be avoided in regions with fluoroquinolone resistance rates >20% among E. coli isolates, as recommended by the Praxis Medical Insights 1
• Delayed source control can lead to inadequate treatment of intra-abdominal infections, as reported by the World Journal of Emergency Surgery 2

Emerging Treatment Options

• Newer agents like ceftolozane/tazobactam and ceftazidime/avibactam should be reserved for multidrug-resistant infections to preserve their activity, as recommended by the Praxis Medical Insights 1
• "Old" antibiotics such as polymyxins (colistin) and fosfomycin have been revived for treating carbapenem-resistant infections but should be used judiciously, according to the World Journal of Emergency Surgery and Praxis Medical Insights 2, 1
• Tigecycline is a viable treatment option for complicated intra-abdominal infections due to its favorable activity against anaerobic organisms and several ESBL-producing Enterobacteriaceae, as reported by the World Journal of Emergency Surgery 2

Treatment of ESBL-Producing Bacterial Infections

Introduction to ESBL Treatment

• The World Health Organization recommends piperacillin/tazobactam, ceftazidime/avibactam, and ceftolozane/tazobactam as alternatives to carbapenems for the treatment of ESBL-producing bacterial infections in stable patients 5
• The Infectious Diseases Society of America suggests that ceftazidime/avibactam and meropenem/vaborbactam are first-line options for KPC-producing carbapenem-resistant Enterobacteriaceae 6

Special Considerations for Resistance Mechanisms

• The European Society of Clinical Microbiology and Infectious Diseases recommends ceftazidime/avibactam plus aztreonam for MBL-producing Enterobacterales, as MBLs hydrolyze all β-lactams except monobactams 6

Carbapenem-Sparing Strategies

• The American Society of Health-System Pharmacists suggests that newer β-lactam/β-lactamase inhibitor combinations, such as ceftazidime/avibactam and ceftolozane/tazobactam, should be reserved for multidrug-resistant infections to preserve their activity 5
• The Society of Infectious Diseases Pharmacists recommends tigecycline as a viable option for complicated intra-abdominal infections with favorable activity against ESBL-producers, though it lacks activity against P. aeruginosa and should be used cautiously in suspected bacteremia 5

Treatment of ESBL-Producing Bacterial Infections

Severity-Based Treatment Algorithm

• For critically ill patients or those with septic shock, the World Journal of Emergency Surgery recommends initiating Group 2 carbapenems (meropenem 1g IV q6h by extended infusion, imipenem/cilastatin 500mg IV q6h by extended infusion, or doripenem 500mg IV q8h by extended infusion) immediately as first-line therapy 7
• Eravacycline 1 mg/kg IV every 12 hours is an alternative for beta-lactam allergies, as recommended by the World Journal of Emergency Surgery 7
• Ertapenem 1g IV every 24 hours is suitable for patients with inadequate/delayed source control or high risk of community-acquired ESBL infections, according to the World Journal of Emergency Surgery 7

Site-Specific Considerations

• For non-critically ill, immunocompetent patients with adequate source control and intra-abdominal infections, the World Journal of Emergency Surgery recommends Amoxicillin/clavulanate 2g/0.2g IV every 8 hours 7
• For critically ill or immunocompromised patients with intra-abdominal infections, the World Journal of Emergency Surgery recommends Piperacillin/tazobactam 6g/0.75g loading dose, then 4g/0.5g IV every 6 hours or 16g/2g by continuous infusion 7
• For high risk for ESBL or inadequate source control, the World Journal of Emergency Surgery recommends Ertapenem 1g IV every 24 hours or eravacycline 1 mg/kg IV every 12 hours 7

Critical Pitfalls to Avoid

• Delayed source control leads to treatment failure in intra-abdominal infections, as noted by the World Journal of Emergency Surgery 7

Treatment of ESBL-Positive Infections

Carbapenem-Sparing Strategies

• The World Health Organization recommends ceftolozane/tazobactam plus metronidazole as an effective treatment for ESBL-producing Enterobacteriaceae, which helps preserve carbapenems 8, 9
• The Infectious Diseases Society of America suggests that tigecycline at high doses plus carbapenem in continuous infusion may be considered for carbapenem-resistant Enterobacteriaceae, with the addition of IV colistin in severe infections 10
• The European Society of Clinical Microbiology and Infectious Diseases recommends avoiding extended use of cephalosporins and fluoroquinolones due to selective pressure for ESBLs and MRSA, and instead reserve newer agents like ceftolozane/tazobactam and ceftazidime/avibactam for multidrug-resistant infections 11

Monitoring and Local Epidemiology

• The Centers for Disease Control and Prevention advise monitoring serum levels of aminoglycosides and vancomycin closely to decrease the risk of renal failure 10
• The World Health Organization suggests that local antimicrobial resistance patterns and bacterial ecology must guide empiric therapy choices, with rapid identification of the specific resistance mechanism crucial for optimizing therapy 11

Carbapenem Stewardship and Reserved Alternatives in Patients with Renal Failure

Guideline Recommendations (WSES)

Reserved Alternative Agents

Guideline Recommendations for Piperacillin‑Tazobactam Use in ESBL‑Producing Enterobacterales

First‑Line Therapy Recommendations

• The 2022 ESCMID guideline recommends carbapenems (e.g., meropenem, imipenem‑cilastatin, doripenem) as the first‑line agents for serious ESBL‑producing Enterobacterales infections, and advises against using piperacillin‑tazobactam in critically ill patients or those with high‑risk sources of bacteremia. 16

Situations Where Piperacillin‑Tazobactam May Be Considered

• According to the 2022 ESCMID guideline, piperacillin‑tazobactam can be used as a carbapenem‑sparing alternative in hemodynamically stable patients with uncomplicated urinary tract or soft‑tissue infections caused by ESBL‑producing E. coli, provided the isolate is susceptible in vitro. 16
• The ESCMID guideline also permits step‑down targeted therapy with piperacillin‑tazobactam after an initial course of carbapenem once the patient is stabilized and susceptibility results confirm activity. 16

Cautionary Evidence on Efficacy

• The American Journal of Respiratory and Critical Care Medicine (2005) cautions that both third‑generation cephalosporins and piperacillin‑tazobactam have uncertain efficacy against ESBL organisms even when administered at adequate doses. 17

Risks of Empirical Use in Critically Ill Patients

• Data published in Annals of Oncology (2015) show that empirical use of piperacillin‑tazobactam in critically ill patients with suspected ESBL infection is linked to higher mortality, primarily due to delayed initiation of effective therapy. 18

Empiric Antibiotic Strategies for Multidrug‑Resistant Klebsiella

Carbapenem‑Sparing Regimens for ESBL‑Producing Infections

• In hemodynamically stable patients with adequate source control, a regimen of ceftazidime‑avibactam plus metronidazole provides an effective carbapenem‑sparing option and retains activity against KPC‑producing Klebsiella strains. 19
• Metronidazole must be added to ceftazidime‑avibactam because the latter has limited activity against anaerobic organisms that may be present in intra‑abdominal or polymicrobial infections. 19

First‑Line Therapy for Confirmed or Suspected Carbapenem‑Resistant Klebsiella (CRE/KPC)

• When carbapenem resistance is documented or highly suspected, ceftazidime‑avibactam should be used as the preferred agent because it consistently inhibits KPC‑producing Klebsiella pneumoniae. 19
• Meropenem‑vaborbactam also demonstrates reliable activity against KPC producers and supplies intrinsic anaerobic coverage, eliminating the need for an additional anaerobic agent. 20

Agents to Avoid in ESBL‑Producing or MDR Klebsiella

• Third‑generation cephalosporins (e.g., ceftriaxone, cefotaxime, ceftazidime) should never be employed for ESBL‑producing Klebsiella, even when in‑vitro susceptibility appears favorable, due to a high rate of clinical failure. 19
• Prolonged or empirical use of third‑generation cephalosporins in settings with a high prevalence of ESBLs should be discouraged because it creates selective pressure that promotes further resistance. 19
• Fluoroquinolones are contraindicated for ESBL‑producing Klebsiella owing to very high resistance rates (≈ 96 % in reported series) and their contribution to ESBL emergence. 19

Antimicrobial Stewardship: De‑escalation and Carbapenem Conservation

• Implementing de‑escalation (e.g., switching from a carbapenem to ceftazidime‑avibactam when susceptibility is confirmed and the patient is clinically stable) is linked to reduced ICU mortality and is a core stewardship practice. 19
• Overuse of carbapenems drives selection pressure and the emergence of carbapenem‑resistant organisms; therefore, carbapenem‑sparing alternatives such as ceftazidime‑avibactam (with metronidazole) or meropenem‑vaborbactam should be employed whenever clinically appropriate. 19, 20